Difference between revisions of "Imipramine-mirtazapine"

From Psychiatrienet
Jump to: navigation, search
Line 9: Line 9:
 
* '''Day 1:''' simultaneously start administration of mirtazapine in a normal dosage of 30 mg/day.
 
* '''Day 1:''' simultaneously start administration of mirtazapine in a normal dosage of 30 mg/day.
 
* '''Day 8:''' stop administration of imipramine and continue administration of mirtazapine.
 
* '''Day 8:''' stop administration of imipramine and continue administration of mirtazapine.
 +
|info =
 +
{{review}}
 
}}
 
}}

Revision as of 08:47, 4 November 2015

Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine

Switch medication from imipramine to mirtazapine.[1] [2]

Nietinrijdenbord.png Stop imipramine
  • Before day 1: gradually reduce dosage of imipramine to a maximum of 75 mg/day.
  • Day 1: reduce dosage of imipramine to 50 mg/day.
  • Day 3: reduce dosage of imipramine to 25 mg/day.
Eenrichtingbord.png Start mirtazapine
  • Day 1: simultaneously start administration of mirtazapine in a normal dosage of 30 mg/day.
  • Day 8: stop administration of imipramine and continue administration of mirtazapine.
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.